BINDING MOLECULES ORIGINATING FROM IMMUNOGLOBULINS THAT DO NOT STIMULATE COMPLEMENT-MEDIATED LYSIS Russian patent published in 2004 - IPC

FIELD: recombinant proteins, immunology, pharmacy. SUBSTANCE: invention relates to group of new compounds that are binding molecules representing a recombinant polypeptide antibody or adhesion molecule comprising: (i) binding domain that is able to bind with a target-molecule; (ii) effector domain having amino acid sequence that is shows homology mainly with all constant domain of human immunoglobulin heavy chain or with its part wherein a binding molecule is able to bind with a target-molecule but without stimulation of significant complement-dependent lysis or cell-mediated destruction of target. Effector domain shows capacity to bind specifically with FcRn and/or FcγRIIb and represents chimeric domain that originates from domains C_H2 of heavy chain of two or more human immunoglobulins being human immunoglobulins are taken among IgG1, IgG2 and IgG4 and wherein chimeric domain represents the domain C_H2 of human immunoglobulins heavy chain that comprises the following blocks of amino acids in the claimed positions: 233P, 234V, 235A and 236G, and 327G, 330S and 331A in accordance with the numeration system EU and can represent at least 98% of similarity with sequence C_H2 (residues 231-340) in human IgG1, IgG2 having indicated modified amino acids; and also to isolated nucleic acid comprising nucleotide sequence encoding effector domain of a binding molecule; to replicating virus comprising this nucleic acid; to method for preparing a binding molecule; to method for binding target-molecule and pharmaceutical preparation containing a binding molecule. EFFECT: valuable biological properties of molecules. 24 cl, 25 dwg